Nu Skin Enterprises, Inc. (NYSE:NUS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm presently has a $70.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 11.39% from the stock’s previous close.

According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “

NUS has been the topic of a number of other reports. Pivotal Research restated a “buy” rating and issued a $65.00 target price on shares of Nu Skin Enterprises in a report on Thursday, May 4th. ValuEngine upgraded shares of Nu Skin Enterprises from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Sidoti lowered shares of Nu Skin Enterprises from a “buy” rating to a “neutral” rating and set a $59.00 price objective on the stock. in a report on Wednesday, April 26th. Bank of America Corporation increased their price objective on shares of Nu Skin Enterprises from $53.00 to $57.00 and gave the stock an “underperform” rating in a report on Monday. Finally, Deutsche Bank AG increased their price objective on shares of Nu Skin Enterprises from $63.00 to $66.00 and gave the stock a “buy” rating in a report on Wednesday, June 21st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $62.25.

Nu Skin Enterprises (NYSE:NUS) traded down 0.10% during trading on Wednesday, hitting $62.84. 436,913 shares of the stock traded hands. The company’s 50 day moving average price is $58.20 and its 200-day moving average price is $53.72. Nu Skin Enterprises has a 52-week low of $45.00 and a 52-week high of $66.04. The stock has a market cap of $3.32 billion, a P/E ratio of 20.86 and a beta of 1.32.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Wednesday, May 3rd. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.50 by $0.01. Nu Skin Enterprises had a net margin of 7.48% and a return on equity of 23.45%. The business had revenue of $499.10 million for the quarter, compared to analyst estimates of $493.65 million. During the same period in the previous year, the firm earned $0.42 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts forecast that Nu Skin Enterprises will post $3.12 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 14th. Shareholders of record on Friday, May 26th were given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 2.29%. The ex-dividend date of this dividend was Wednesday, May 24th. Nu Skin Enterprises’s dividend payout ratio (DPR) is 48.48%.

COPYRIGHT VIOLATION WARNING: “Nu Skin Enterprises, Inc. (NUS) Lifted to Buy at Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/12/nu-skin-enterprises-inc-nus-lifted-to-buy-at-zacks-investment-research.html.

In other news, General Counsel D Matthew Dorny sold 8,000 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $56.39, for a total transaction of $451,120.00. Following the completion of the transaction, the general counsel now directly owns 52,730 shares in the company, valued at approximately $2,973,444.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 24,250 shares of company stock valued at $1,436,770 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in NUS. Russell Investments Group Ltd. acquired a new position in Nu Skin Enterprises during the fourth quarter valued at approximately $3,124,000. State Street Corp boosted its position in Nu Skin Enterprises by 2.4% in the fourth quarter. State Street Corp now owns 802,056 shares of the company’s stock valued at $38,321,000 after buying an additional 18,471 shares during the period. Dimensional Fund Advisors LP boosted its position in Nu Skin Enterprises by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 947,226 shares of the company’s stock valued at $45,260,000 after buying an additional 39,926 shares during the period. Renaissance Technologies LLC boosted its position in Nu Skin Enterprises by 269.9% in the fourth quarter. Renaissance Technologies LLC now owns 200,100 shares of the company’s stock valued at $9,561,000 after buying an additional 146,000 shares during the period. Finally, New York State Teachers Retirement System boosted its position in Nu Skin Enterprises by 2.1% in the fourth quarter. New York State Teachers Retirement System now owns 4,900 shares of the company’s stock valued at $234,000 after buying an additional 100 shares during the period. Institutional investors own 85.54% of the company’s stock.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.